Current Cardiology Reports

, Volume 8, Issue 4, pp 296–300

Acute coronary syndromes in patients with renal disease: What are the issues?

  • Carmelo J. Panetta
  • Charles A. Herzog
  • Timothy D. Henry


Patients with chronic kidney disease and acute coronary syndromes are at high risk for both bleeding and ischemic events. This risk increases with the severity of renal insufficiency. Management for acute coronary syndromes in the setting of kidney disease is a paradox; as the benefit of current treatment is high, so is the risk for complications. Patients with chronic renal disease are frequently excluded from randomized clinical trials, and therefore, the optimal treatment strategies are often speculative in this high-risk patient population. Additional research is needed to further refine the optimal management of patients with chronic kidney disease in the setting of acute coronary syndromes.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Kidney disease research updates. http://kidney.niddk.nih. gov/about/Research_Updates/KidneyDiseaseFall05/1.htmGoogle Scholar
  2. 2.
    Jaar BG, Coresh J, Plantinga LC, et al.: Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005, 143:174–183.PubMedGoogle Scholar
  3. 3.
    Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974, 290:697–701.PubMedCrossRefGoogle Scholar
  4. 4.
    USRDS, Morbidity and Mortality. http://www.usrds. org/2005/pdf/06_morb_and_mort_05.pdfGoogle Scholar
  5. 5.
    •• Go AS, Chertow GM, Fan D, et al.: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296–1305.Large sample size analysis to define the cardiovascular risk for CKD patientsPubMedCrossRefGoogle Scholar
  6. 6.
    Brugts JJ, Knetsch AM, Mattace-Raso FU, et al.: Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med 2005, 165:2659–2665.PubMedCrossRefGoogle Scholar
  7. 7.
    •• Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998, 339:799–805.Study that describes the very high mortality in patients on dialysis who have MIPubMedCrossRefGoogle Scholar
  8. 8.
    • Gibson CM, Dumaine RL, Gelfand EV, et al.: Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J 2004, 25:1998–2005.A large study that describes the mortality associated with ACS and CKDPubMedCrossRefGoogle Scholar
  9. 9.
    Kirtane AJ, Leder DM, Waikar SS, et al.: Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol 2005, 45:1781–1786.PubMedCrossRefGoogle Scholar
  10. 10.
    Dumaine R, Collet JP, Tanguy ML, et al.: Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). Am J Cardiol 2004, 94:1543–1547.PubMedCrossRefGoogle Scholar
  11. 11.
    Shlipak MG, Heidenreich PA, Noguchi H, et al.: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002, 137:555–562.PubMedGoogle Scholar
  12. 12.
    Wright RS, Reeder GS, Herzog CA, et al.: Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002, 137:563–570.PubMedGoogle Scholar
  13. 13.
    • Sadeghi HM, Stone GW, Grines CL, et al.: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003, 108:2769–2775. Large study describing the increased risk for bleeding, death, and restenosis for those with CKD and ACSPubMedCrossRefGoogle Scholar
  14. 14.
    • Best PJ, Lennon R, Ting HH, et al.: The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002, 39:1113–1119. Early study describing the impact of CKD after PCIPubMedCrossRefGoogle Scholar
  15. 15.
    Asinger RW, Henry TD, Herzog CA, et al.: Clinical outcomes of PTCA in chronic renal failure: a case-control study for comorbid features and evaluation of dialysis dependence. J Invasive Cardiol 2001, 13:21–28.PubMedGoogle Scholar
  16. 16.
    Berger PB, Best PJ, Topol EJ, et al.: The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 2005, 149:869–875.PubMedCrossRefGoogle Scholar
  17. 17.
    Rihal CS, Textor SC, Grill DE, et al.: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105:2259–2264.PubMedCrossRefGoogle Scholar
  18. 18.
    • Freeman RV, Mehta RH, Al Badr W, et al.: Infiuence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003, 41:718–724.Early study describing increased bleeding, but benefit from GP IIb/IIIa inhibitors in those with CKD and ACSPubMedCrossRefGoogle Scholar
  19. 19.
    de Lusignan S, Chan T, Stevens P, et al.: Identifying patients with chronic kidney disease from general practice computer records. Fam Pract 2005, 22:234–241.PubMedCrossRefGoogle Scholar
  20. 20.
    Bolton K, Culleton B, Harvey KS, et al.: Part 4: Clinical practice guidelines for chronic kidney disease. Evaluation, classification, stratification. Am J Kidney Dis 2002, 39:S46-S75.CrossRefGoogle Scholar
  21. 21.
    Manske CL, Thomas W, Wang Y, Wilson RF: Screening diabetic transplant candidates for coronary artery disease: identification of a low risk subgroup. Kidney Int 1993, 44:617–621.PubMedCrossRefGoogle Scholar
  22. 22.
    Hergesell O, Zeier M: Underdiagnosis of diabetes mellitus in chronic dialysis patients on the renal transplant waiting list. Transplant Proc 2003, 35:1287–1289.PubMedCrossRefGoogle Scholar
  23. 23.
    Creager MA, Luscher TF, Cosentino F, et al.: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003, 108:1527–1532.PubMedCrossRefGoogle Scholar
  24. 24.
    Stack AG, Bloembergen WE: Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 2001, 12:1516–1523.PubMedGoogle Scholar
  25. 25.
    Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643–2653.PubMedCrossRefGoogle Scholar
  26. 26.
    Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.PubMedCrossRefGoogle Scholar
  27. 27.
    O#x2019;Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996, 27:84–91.Google Scholar
  28. 28.
    • Vaitkus, PT. Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. Am Heart J 2000, 139:1000–1008.Thorough review of hyperlipidemia in those with CKDPubMedCrossRefGoogle Scholar
  29. 29.
    Corsini, A: The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 2003, 17:265–285.PubMedCrossRefGoogle Scholar
  30. 30.
    • Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238–248.Key study implying statin therapy in those with diabetes mellitus and dialysis may not benefit as predictedPubMedCrossRefGoogle Scholar
  31. 31.
    Abbas NA, John RI, Webb MC, et al.: Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem 2005, 51:2059–2066.PubMedCrossRefGoogle Scholar
  32. 32.
    K/DOQI Workgroup: K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005, 45:S1–S153. Thorough review of management for patients on dialysis for cardiovascular disease, including a comprehensive section on cardiac markersGoogle Scholar
  33. 33.
    Khan NA, Hemmelgarn BR, Tonelli M, et al.: Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 2005, 112:3088–3096.PubMedCrossRefGoogle Scholar
  34. 34.
    Gruberg L, Fuchs S, Waksman R, et al.: Prognostic value of cardiac troponin I elevation after percutaneous coronary intervention in patients with chronic renal insufficiency: a 12-month outcome analysis. Catheter Cardiovasc Interv 2002, 55:174–179.PubMedCrossRefGoogle Scholar
  35. 35.
    Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003, 42:201–208.PubMedCrossRefGoogle Scholar
  36. 36.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.PubMedCrossRefGoogle Scholar
  37. 37.
    Mann JF, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629–636.PubMedGoogle Scholar
  38. 38.
    Verma S, Strauss M: Angiotensin receptor blockers and myocardial infarction. BMJ 2004, 329:1248–1249.PubMedCrossRefGoogle Scholar
  39. 39.
    Grand#x2019;Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs 2005, 5:291–305.CrossRefGoogle Scholar
  40. 40.
    Farooq V, Hegarty J, Chandrasekar T, et al.: Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004, 43:531–537.PubMedCrossRefGoogle Scholar
  41. 41.
    Green B, Greenwood M, Saltissi D, et al.: Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2005, 59:281–290.PubMedCrossRefGoogle Scholar
  42. 42.
    Collet JP, Montalescot G, Agnelli G, et al.: Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J 2005, 26:2285–2293.PubMedCrossRefGoogle Scholar
  43. 43.
    Chew DP, Bhatt DL, Kimball W, et al.: Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003, 92:919–923.PubMedCrossRefGoogle Scholar
  44. 44.
    • Chew DP, Lincoff AM, Gurm H, et al.: Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 2005, 95:581–585.Study that implies that bivalirudin, although cleared by the kidney, is still effective with fewer bleeding events compared with standard therapyPubMedCrossRefGoogle Scholar
  45. 45.
    Henry TD, Schweizer M, MacDonald H, et al.: Use of bivalirudin in patients with severe renal dysfunction [abstract]. Catheter Cardiovasc Interv 2004, 62:133.Google Scholar
  46. 46.
    Keough-Ryan TM, Kiberd BA, Dipchand CS, et al.: Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kidney Dis 2005, 46:845–855.PubMedCrossRefGoogle Scholar
  47. 47.
    McCullough PA, Sandberg KR: Epidemiology of contrastinduced nephropathy. Rev Cardiovasc Med 2003, 4:S3-S9.Google Scholar
  48. 48.
    Tadros GM, Malik JA, Manske CL, et al.: Iso-osmolar radio contrast iodixanol in patients with chronic kidney disease. J Invasive Cardiol 2005, 17:211–215.PubMedGoogle Scholar
  49. 49.
    Aspelin P, Aubry P, Fransson SG, et al.: Nephrotoxicity effects in high-risk patients undergoing angioplasty. N Engl J Med 2003, 348:491–499.PubMedCrossRefGoogle Scholar
  50. 50.
    Manske CL, Wang Y, Rector T, et al.: Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992, 340:998–1002.PubMedCrossRefGoogle Scholar
  51. 51.
    • Herzog CA, Ma JZ, Collins AJ: Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002, 106:2207–2211.Study implying CABG in dialysis patients had a better outcome compared with PCI in the era before drug-eluting stentsPubMedCrossRefGoogle Scholar
  52. 52.
    Azar RR, Prpic R, Ho KK, et al.: Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting. Am J Cardiol 2000, 86:485–489.PubMedCrossRefGoogle Scholar
  53. 53.
    Lemos PA, Arampatzis CA, Hoye A, et al.: Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol 2005, 95:167–172.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Carmelo J. Panetta
  • Charles A. Herzog
  • Timothy D. Henry
    • 1
  1. 1.Minneapolis Heart Institute FoundationMinneapolisUSA

Personalised recommendations